News Feed Item

Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan

TOKYO, Oct 13, 2017 - (JCN Newswire) - Eisai Co., Ltd., Toyama Chemical Co., Ltd. of the Fujifilm Group and Taisho Pharmaceutical Co., Ltd. today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd.

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.
guratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying AntiRheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram Tablets 25 mg and KOLBET Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.
About anti-rheumatic agent KOLBET Tablets 25 mg (generic name: iguratimod)

Indications and Usage: Rheumatoid arthritis
Dosage and Administration: The recommended adult dosage of iguratimod is one 25 mg tablet taken orally once daily after breakfast for at least four weeks, after which the dosage should be increased to one 25 mg tablet taken twice daily (after breakfast and after dinner).

About Toyama Chemical Co., Ltd.

Toyama Chemical Co., Ltd. is a core company of the Fujifilm Group responsible for the "treatment" area of Fujifilm's healthcare business. It works to develop innovative new medicines in its primary focus areas of infectious diseases, neurological diseases, and inflammatory diseases. By producting stable new drug candidates of an international standard and combining them with Fujifilm's technology, it aims to further strengthen its R&D and production capibilities. Toyama Chemical specializes in pharmaceutical research and development, and strives to contribute to the further development of global health care through new drug development. For more information about Toyama Chemical Co., Ltd., please visit www.toyama-chemical.co.jp/en/.

About Taisho Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Co., Ltd. conducts research, development, manufacturing and marketing of over-the-counter (OTC) medicine, special health foods, food products, medical products, and hygiene products (self-medication business) as well as research, development, manufacturing and marketing of ethical pharmaceuticals (prescription pharmaceutical business). While leading the market with top-share OTC medicines including Lipovitan D, Pavulon, and RiUP, Taisho Pharmaceutical is enhancing its development capabilities for new prescription medicines. While exploiting the synergy between these two businesses, it seeks to contribute to the realization of a healthier and more prosperous life that everyone desires. For more information about Taisho Pharmaceutical Co., Ltd., please visit www.taisho.co.jp/en/.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Source: Eisai

Public Relations Department,
Eisai Co., Ltd.

Copyright 2017 JCN Newswire . All rights reserved.

More Stories By ACN Newswire

Copyright 2008 ACN Newswire. All rights reserved. Republication or redistribution of ACN Newswire content is expressly prohibited without the prior written consent of ACN Newswire. ACN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
How is DevOps going within your organization? If you need some help measuring just how well it is going, we have prepared a list of some key DevOps metrics to track. These metrics can help you understand how your team is doing over time. The word DevOps means different things to different people. Some say it a culture and every vendor in the industry claims that their tools help with DevOps. Depending on how you define DevOps, some of these metrics may matter more or less to you and your team.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...